Sun Pharmaceutical Industries Ltd vs Syncom Formulations India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 11, 2026

Key Highlights

The Latest Trading Price of Sun Pharmaceutical Industries Ltd is ₹ 1787 as of 10 Jun 15:30 . The P/E Ratio of Sun Pharmaceutical Industries Ltd changed from 67.1 on March 2022 to 49.4 on March 2021 . This represents a CAGR of -5.94% over 5 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 years The Market Cap of Sun Pharmaceutical Industries Ltd changed from ₹ 219491 crore on March 2022 to ₹ 143384 crore on March 2021 . This represents a CAGR of -8.16% over 5 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 years The revenue of Sun Pharmaceutical Industries Ltd for the Mar '26 is ₹ 15070 crore as compare to the Dec '25 revenue of ₹ 16099 crore. This represent the decline of -6.39% The revenue of Syncom Formulations (India) Ltd for the Mar '26 is ₹ 149.97 crore as compare to the Dec '25 revenue of ₹ 120.64 crore. This represent the growth of 24.31% The ebitda of Sun Pharmaceutical Industries Ltd for the Mar '26 is ₹ 4412 crore as compare to the Dec '25 ebitda of ₹ 5037 crore. This represent the decline of -12.41% The ebitda of Syncom Formulations (India) Ltd for the Mar '26 is ₹ 36.56 crore as compare to the Dec '25 ebitda of ₹ 26.71 crore. This represent the growth of 36.88% The net profit of Sun Pharmaceutical Industries Ltd changed from ₹ 2871 crore to ₹ 2723 crore over 8 quarters. This represents a CAGR of -2.60% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 25.17 crore over 8 quarters. This represents a CAGR of 81.63% The Dividend Payout of Sun Pharmaceutical Industries Ltd changed from 213.61 % on March 2021 to 89.64 % on March 2025 . This represents a CAGR of -15.94% over 5 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Sun Pharmaceutical Industries Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Sun Pharmaceutical Industries Ltd or Syncom Formulations (India) Ltd?

Market cap of Sun Pharmaceutical Industries Ltd is 428,785 Cr while Market cap of Syncom Formulations (India) Ltd is 1,327 Cr

What are the key factors driving the stock performance of Sun Pharmaceutical Industries Ltd and Syncom Formulations (India) Ltd?

The stock performance of Sun Pharmaceutical Industries Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sun Pharmaceutical Industries Ltd and Syncom Formulations (India) Ltd?

As of June 11, 2026, the Sun Pharmaceutical Industries Ltd stock price is INR ₹1787.1. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹14.12.

How do dividend payouts of Sun Pharmaceutical Industries Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Sun Pharmaceutical Industries Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.